Biogen (BIIB.US) stock has been halted after the FDA has approved its controversial Alzheimer drug Aducanumab using an accelerated approval pathway. It is the first Alzheimer's treatment approved in 18 years, according to CNBC. Biogen still needs to conduct a postapproval clinical trial and FDA pointed out that the approval may be withdrawn upon unfavorable results.
Biogen (BIIB.US) stock was halted for trading at $286.10 and awaits reopening. Source: xStation5
Daily Summary: Trump’s UN Speech Puts Iran, Hormuz and AI in the Spotlight
AWS Gets NATO Approval. Opening the Door to More Defense Contracts
AMD Surpasses One Trillion Dollars in Market Capitalization. Now Wall Street Is Raising the Bar
US OPEN: Tech is looking for a reason to grow, diplomacy in the background